US4493848A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Compositions and methods useful for producing analgesia
Assignee: Procter and Gamble Co
•
Filing: 1983-07-14
•
Granted: 1985-01-15
•
Expires: 2003-07-14
Abstract
Abstract A composition, useful for producing analgesia in humans or lower animals, comprising a safe and effective amount of: an N-[(substituted phenyl)methyl]-cis-monounsaturated alkenamide pharmaceutically-acceptable salts thereof, or mixtures thereof; and a pharmaceutically-acceptable carrier. Preferably, these alkenamides are N-vanillyl-cis-monounsaturated alkenamides. Methods of treatment, comprising administering a safe and effective amount of these alkenamides, pharmaceutically-acceptable salts thereof, or mixtures thereof, include methods of parenteral, oral, and topical administration.
Inventors
- 👤 Thomas R. LaHann
- 👤 Brian L. Buckwalter
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 03:42
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/16; A61P; A61P25/00; A61P25/04
Claims Analysis
Total Claims: 16
Claim 1
Independent Claim
93 words
A method for producing analgesia in humans or lower animals, which comprises administering to said human or lower animal a safe and effective amount of a monoalkenamide compound or pharmaceutically-acceptable salt thereof, or mixtures thereof, of the formula: ##STR5## wherein X is O or S; R is straight or branched, cis-monounsaturated alkenyl having from 11 to 23 carbon atoms; R 1 is H, OH, or OCH 3 ; R 2 is OH, or a short-chain ester; and wherein at least one of R 1 and R 1 is OH or OCH 3 .
Claim 2
Independent Claim
93 words
A method for producing analgesia in humans or lower animals, which comprises administering to said human or lower animal a safe and effective amount of a monoalkenamide compound or pharmaceutically-acceptable salt thereof, or mixtures thereof, of the formula: ##STR5## wherein X is O or S; R is straight or branched, cis-monounsaturated alkenyl having from 11 to 23 carbon atoms; R 1 is H, OH, or OCH 3 ; R 2 is OH, or a short-chain ester; and wherein at least one of R 1 and R 1 is OH or OCH 3 .
Claim 3
Dependent Claim
25 words
A method, according to claim 1, wherein R of said monoalkenamide compound is straight or branched, cis-monounsaturated alkenyl having from 16 to 21 carbon atoms.
Claim 4
Dependent Claim
30 words
A method, according to claim 1, wherein said monoalkenamide compound is selected from the group consisting of N-vanillyl-9Z-tetradecenamide, N-vanillyl-9Z-octadecenamide, N-vanillyl-6Z-octadecenamide, N-vanillyl-11Z-octadecenamide, N-vanillyl-10Z-nonadecenamide, N-vanillyl-13Z-docosenamide, and pharmaceutically-acceptable salts thereof and mixtures thereof.
Claim 5
Dependent Claim
12 words
A method, according to claim 2, wherein said monoalkenamide is administered intramuscularly.
Claim 6
Dependent Claim
20 words
A method, according to claim 2, for producing analgesia in humans or lower animals, wherein said monoalkenamide is administered orally.
Claim 7
Dependent Claim
12 words
A method, according to claim 2, wherein said monoalkenamide is administered topically.
Claim 8
Dependent Claim
91 words
A composition for producing analgesia in humans or lower animals, comprising: (a) a safe and effective amount of a monoalkenamide compound or pharmaceutically-acceptable salt thereof, or mixtures thereof, of the formula: ##STR6## wherein X is O or S, R is straight or branched cis-monounsaturated alkenyl having from 11 to 23 carbon atoms, R 1 is H, OH, or OCH 3 , R 2 is OH or a short-chain ester, and wherein at least one of R 1 and R 2 is OH or OCH 3 ; and (b) a pharmaceutically-acceptable carrier.
Claim 9
Dependent Claim
91 words
A composition for producing analgesia in humans or lower animals, comprising: (a) a safe and effective amount of a monoalkenamide compound or pharmaceutically-acceptable salt thereof, or mixtures thereof, of the formula: ##STR6## wherein X is O or S, R is straight or branched cis-monounsaturated alkenyl having from 11 to 23 carbon atoms, R 1 is H, OH, or OCH 3 , R 2 is OH or a short-chain ester, and wherein at least one of R 1 and R 2 is OH or OCH 3 ; and (b) a pharmaceutically-acceptable carrier.
Claim 10
Dependent Claim
21 words
A composition, according to claim 7, wherein R is straight or branched, cis-monounsaturated alkenyl having from 16 to 21 carbon atoms.
Claim 11
Dependent Claim
17 words
A composition, according to claim 7, wherein R 1 is OCH 3 and R 2 is OH.
Claim 12
Dependent Claim
27 words
A composition, according to claim 7, comprising a pharmaceutically-acceptable salt of said monoalkenamide compound, selected from the group consisting of sodium, potassium, calcium, magnesium, and ammonium salts.
Claim 13
Dependent Claim
30 words
A composition, according to claim 9, wherein said monoalkenamide compound is selected from the group consisting of N-vanillyl-9Z-tetradecenamide, N-vanillyl-9Z-octadecenamide, N-vanillyl-6Z-octadecenamide, N-vanillyl-11Z-octadecenamide, N-vanillyl-10Z-nonadecenamide, N-vanillyl-13Z-docosenamide, and pharmaceutically-acceptable salts thereof and mixtures thereof.
Claim 14
Dependent Claim
11 words
A composition, according to claim 11, wherein said monoalkenamide is N-vanillyl-9Z-octadecenamide.
Claim 15
Dependent Claim
20 words
A composition, according to claim 9, for parenteral administration, comprising at least about 90%, by weight, of said pharmaceutically-acceptable carrier.
Claim 16
Dependent Claim
21 words
A composition, according to claim 9, for oral administration, comprising from about 25% to about 50%, by weight, of said monoalkenamide.
References Cited (Backward Citations)
FR1336388A
Cited
US3268582A
Cited
BE626897A
Cited
US4238508A
Cited
US4313958A
Cited
US4401663A
Cited
JPS6139413A
Cited
JPS6147752A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1988-01-15 | 1988-07-16 | 1989-01-15 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1992-01-15 | 1992-07-16 | 1993-01-15 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1996-01-15 | 1996-07-16 | 1997-01-15 | $7700.00 | Window Closed / Lapsed |